{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:29:46Z","timestamp":1792459786295,"version":"4.5.0"},"reference-count":27,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2011,7,7]],"date-time":"2011-07-07T00:00:00Z","timestamp":1309996800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2011,9]]},"abstract":"<jats:p>Although bendamustine plus rituximab has demonstrated efficacy in indolent B cell non\u2010Hodgkin\u2019s lymphoma (B\u2010NHL), data for this combination in aggressive B\u2010NHL are extremely limited. The present dose\u2010escalation study evaluated the safety, efficacy, and pharmacokinetics of bendamustine hydrochloride in combination with rituximab in patients with relapsed\/refractory, CD20\u2010positive, aggressive B\u2010NHL. Patients received rituximab 375\u2003mg\/m<jats:sup>2<\/jats:sup>, i.v., on Day 1 and bendamustine at either 90 (Cohort 1) or 120\u2003mg\/m<jats:sup>2<\/jats:sup> (Cohort 2), i.v., on Days 2 and 3 of a 21\u2010day cycle. The primary endpoint was the proportion of patients experiencing dose\u2010limiting toxicity (DLT). Secondary endpoints were adverse events (AE), the overall response rate (ORR), and pharmacokinetic parameters. Nine patients received rituximab plus bendamustine: three in Cohort 1 and six in Cohort 2. Histologies included diffuse large B cell lymphoma (<jats:italic>n\u2003<\/jats:italic>=<jats:italic>\u2003<\/jats:italic>5), mantle cell lymphoma (<jats:italic>n\u2003<\/jats:italic>=<jats:italic>\u2003<\/jats:italic>2), and transformed lymphoma (<jats:italic>n\u2003<\/jats:italic>=<jats:italic>\u2003<\/jats:italic>2). No DLT was observed at either dose level. Grade 3\/4 hematologic AE included lymphocytopenia, leukocytopenia, and neutropenia (<jats:italic>n\u2003<\/jats:italic>=<jats:italic>\u2003<\/jats:italic>9 each; 100%), and thrombocytopenia (<jats:italic>n\u2003<\/jats:italic>=<jats:italic>\u2003<\/jats:italic>2; 22%). No Grade 3\/4 gastrointestinal AE were reported. The ORR was 33% (one partial response) in Cohort 1 and 100% (five complete and one partial response) in Cohort 2. The maximum drug concentration and area under the blood concentration\u2013time curve for bendamustine increased dose dependently, with time to maximum blood concentration\u2003=\u20031.0\u2003h in both cohorts; these pharmacokinetic data were similar to those reported previously for single\u2010agent bendamustine in patients with indolent B\u2010NHL. In conclusion, bendamustine 120\u2003mg\/m<jats:sup>2<\/jats:sup> plus rituximab 375\u2003mg\/m<jats:sup>2<\/jats:sup> was feasible and generally well tolerated, with promising efficacy in relapsed or refractory aggressive B\u2010NHL. (<jats:italic>Cancer Sci<\/jats:italic> 2011; 102: 1687\u20131692)<\/jats:p>","DOI":"10.1111\/j.1349-7006.2011.01994.x","type":"journal-article","created":{"date-parts":[[2011,5,30]],"date-time":"2011-05-30T13:50:55Z","timestamp":1306763455000},"page":"1687-1692","source":"Crossref","is-referenced-by-count":24,"title":["Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non\u2010Hodgkin\u2019s lymphoma<sup>6<\/sup>"],"prefix":"10.1111","volume":"102","author":[{"given":"Michinori","family":"Ogura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Taniwaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Ohmachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensei","family":"Tobinai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Japanese Bendamustine Lymphoma Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,7,7]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-199606000-00007"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1061"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2006.09.029"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-005-0074-4"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.cad.0000175587.31940.19"},{"key":"e_1_2_7_7_2","first-page":"1287","article-title":"The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high\u2010dose chemotherapy","volume":"90","author":"Knop S","year":"2005","journal-title":"Haematologica"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf189"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.100"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2010.01633.x"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2010.01635.x"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.5070"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24714"},{"key":"e_1_2_7_14_2","first-page":"33","article-title":"Anti\u2010CD20 antibody (IDEC\u2010C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases","volume":"87","author":"Chow KU","year":"2002","journal-title":"Haematologica"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.0001"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70664-7"},{"key":"e_1_2_7_18_2","volume-title":"Cancer Therapy Evaluation Program: Common Terminology Criteria for Adverse Events v3.0 (CTCAE)","author":"National Cancer Institute, US National Institutes of Health","year":"2006"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_7_20_2","first-page":"119","volume-title":"World Health Organization Classification of Tumors, Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissues","author":"Jaffe ES","year":"2001"},{"key":"e_1_2_7_21_2","first-page":"1860","article-title":"Report of the Committee on Hodgkin\u2019s Disease Staging Classification","volume":"31","author":"Carbone PP","year":"1971","journal-title":"Cancer Res"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-010-1254-8"},{"key":"e_1_2_7_23_2","first-page":"458","article-title":"Pharmacokinetics of bendamustin in patients with malignant tumors (Abstract)","volume":"14","author":"Matthias M","year":"1995","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603776"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0b013e3280149eb1"},{"key":"e_1_2_7_26_2","article-title":"In vitro and ex vivo activity of SDX\u2010105 (bendamustine) in drug\u2010resistant lymphoma cells (Abstract)","volume":"45","author":"Leoni LM","year":"2004","journal-title":"AACR Meeting Abstracts"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512073332305"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1618"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1349-7006.2011.01994.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1349-7006.2011.01994.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T20:54:23Z","timestamp":1697403263000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1349-7006.2011.01994.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,7]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["10.1111\/j.1349-7006.2011.01994.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1349-7006.2011.01994.x","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,7]]}}}